Bile Acids and Portal Hypertension
The recent discovery of bile acid (BA) receptors and a better delineation of the multiple roles of BAs in relevant biological processes have revamped BA research. The vasoactive actions of BAs were recognized more than three decades ago but the underlying mechanisms of the BA-induced vasorelaxation...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-11-01
|
Series: | Annals of Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1665268119310464 |
id |
doaj-329a17f8e4dd4c31ab197d0d72583b24 |
---|---|
record_format |
Article |
spelling |
doaj-329a17f8e4dd4c31ab197d0d72583b242021-06-09T05:53:14ZengElsevierAnnals of Hepatology1665-26812017-11-0116S83S86Bile Acids and Portal HypertensionJuan Pablo Arab0Francisco Barrera1Marco Arrese2Departamento de Gastroenterología, Escuela de Medicina. Pontificia Universidad Católica de Chile. Santiago, Chile; Division of Gastroenterology and Hepatology, Mayo Clinic. Rochester, MN, USADepartamento de Gastroenterología, Escuela de Medicina. Pontificia Universidad Católica de Chile. Santiago, ChileDepartamento de Gastroenterología, Escuela de Medicina. Pontificia Universidad Católica de Chile. Santiago, Chile; Correspondence and reprint request:The recent discovery of bile acid (BA) receptors and a better delineation of the multiple roles of BAs in relevant biological processes have revamped BA research. The vasoactive actions of BAs were recognized more than three decades ago but the underlying mechanisms of the BA-induced vasorelaxation are now being clarified. Recent evidence shows that the BA receptors FXR and TGR5 are expressed in endothelial cells and may have important effects on both systemic and portal circulation. The availability of genetically engineered mice with ablation of BA receptors and the development of BA receptor agonists has allowed to explore the modulation of FXR and, in a lesser extent, of TGR5 in the setting of portal hypertension (PHT) with promising results. In this review, we summarize recent data on how BA-dependent pathways influence several processes that impact in PHT and the preclinical data showing that pharmacological modulation of those pathways may hold promise in the treatment of PHT.http://www.sciencedirect.com/science/article/pii/S1665268119310464Bile acidsHepatic flowPortal hypertensionCirrhosisFarnesoid X receptorFibrosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Juan Pablo Arab Francisco Barrera Marco Arrese |
spellingShingle |
Juan Pablo Arab Francisco Barrera Marco Arrese Bile Acids and Portal Hypertension Annals of Hepatology Bile acids Hepatic flow Portal hypertension Cirrhosis Farnesoid X receptor Fibrosis |
author_facet |
Juan Pablo Arab Francisco Barrera Marco Arrese |
author_sort |
Juan Pablo Arab |
title |
Bile Acids and Portal Hypertension |
title_short |
Bile Acids and Portal Hypertension |
title_full |
Bile Acids and Portal Hypertension |
title_fullStr |
Bile Acids and Portal Hypertension |
title_full_unstemmed |
Bile Acids and Portal Hypertension |
title_sort |
bile acids and portal hypertension |
publisher |
Elsevier |
series |
Annals of Hepatology |
issn |
1665-2681 |
publishDate |
2017-11-01 |
description |
The recent discovery of bile acid (BA) receptors and a better delineation of the multiple roles of BAs in relevant biological processes have revamped BA research. The vasoactive actions of BAs were recognized more than three decades ago but the underlying mechanisms of the BA-induced vasorelaxation are now being clarified. Recent evidence shows that the BA receptors FXR and TGR5 are expressed in endothelial cells and may have important effects on both systemic and portal circulation. The availability of genetically engineered mice with ablation of BA receptors and the development of BA receptor agonists has allowed to explore the modulation of FXR and, in a lesser extent, of TGR5 in the setting of portal hypertension (PHT) with promising results. In this review, we summarize recent data on how BA-dependent pathways influence several processes that impact in PHT and the preclinical data showing that pharmacological modulation of those pathways may hold promise in the treatment of PHT. |
topic |
Bile acids Hepatic flow Portal hypertension Cirrhosis Farnesoid X receptor Fibrosis |
url |
http://www.sciencedirect.com/science/article/pii/S1665268119310464 |
work_keys_str_mv |
AT juanpabloarab bileacidsandportalhypertension AT franciscobarrera bileacidsandportalhypertension AT marcoarrese bileacidsandportalhypertension |
_version_ |
1721388804925816832 |